A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2

Array BioPharma

Corresponding author: Array BioPharma

Categories: Oncology
Keywords:

How to cite this poster

Abstract

ARRY-380 is a selective, oral HER2 inhibitor with satisfactory PK, and good predicted target coverage. It is well tolerated with low incidence and severity of diarrhea, rash, fatigue.